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PURPOSE: To analyze the frequency of the delta F508 (∆F508) deletion mutation in 108 unrelated cystic fibrosis
patients and compare the results with the previously reported data for Brazilian patients. Cystic fibrosis is the leading cause
of genetic disease in Caucasians, and the ∆F508 deletion is the most common mutation associated with the disease.
METHOD: The frequency of the ∆F508 mutation was assessed by means of a polymerase chain reaction (PCR)
followed by detection in 8% silver-stained polyacrylamide gels.
RESULTS: Twenty-three of 108 patients (21.3%) were homozygous for the ∆F508 deletion, 50 were heterozygous
(46.3%), and the remaining 35 (32.4%) were non-carriers. In terms of alleles, there were 96 mutated (96/216 or 44.45%) and
120 wild-type ones (120/216 or 55.5%).
CONCLUSION: The 44.45% of affected alleles that were found is higher than the 33% first described in 1993, but
slightly lower than the 48% recently reported. Moreover, our data corroborated the idea that the frequency of the ∆F508
mutation is lower in Brazil in comparison to that found in studies carried out in Europe and North American (circa 70.0%),
probably due to increased racial miscegenation. These findings must be taken into account before any genetic screening of
the population is proposed in Brazil.
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Cystic fibrosis (CF) is the most common potentially le-
thal autosomal recessive disease of Caucasians. The affected
gene, CFTR (cystic fibrosis transmembrane conductance
receptor), has been determined to code for a chloride chan-
nel. Laboratory diagnosis is based on the finding of abnor-
mally high concentrations of chloride in sweat.1 The clini-
cal features of CF are dominated by involvement of the res-
piratory tract, where obstruction of the airways by thick,
sticky mucus and subsequent infection, especially with
Pseudomonas species, predominate. In most patients, there
is also involvement of the intestinal tract leading to pan-
creatic insufficiency as a result of obstruction of the pan-
creatic ducts and subsequent scarring and destruction of
exocrine function.2
The CFTR gene is composed of 250,000 base pairs and
27 exons and encodes a protein of 1,480 amino acids. The
finding that one particular mutation, the delta F508
(∆F508), which is a 3 base-pair deletion in exon 10 of the
CFTR gene corresponding to codon 508 (phenylalanine)
of the protein, is responsible for up to 70.0% of all muta-
tions found in CF patients tested so far has made its mo-
lecular detection a very attractive diagnostic tool.3 How-
ever, it has been shown that the frequency of this mutation
varies significantly among ethnic groups, ranging from
26.0% in Turkey to 88.0% in Denmark.4
A few Brazilian studies carried out in the south and
southeast regions of Brazil found differences with respect
to the frequency of the ∆F508 mutation among CF patients
and also in comparison to those reported in European coun-
tries and in the USA.5 In 24 patients in São Paulo, 33.0%
of alleles were affected;6 In 17 patients in Rio de Janeiro, a
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frequency of 35.0% of affected alleles was found.7 In 190
patients from São Paulo, Paraná, and Rio Grande do Sul,
47.0% had the ∆F508 mutation.8 In another study of 120
chromosomes of 60 patients in São Paulo, a frequency of
31.7% of alleles with the ∆F508 mutation was found.9 In
61 patients from the South of Brazil, 50.8 % of the alleles
had the mutation.10 Of 44 patients from Rio de Janeiro,
47.7% were affected, with a frequency of 30.7% affected
alleles11 More recently, among 160 Brazilian patients in a
study conducted in São Paulo, 48.4% of alleles were af-
fected,12 and in 77 patients from the south of Brazil, 48.7%
of alleles had the ∆F508 mutation.13 Raskin et al. (2004)
concluded that the frequency of the ∆F508 mutation var-
ies remarkably according to geographic and ethnic origin
of patients (Euro-Brazilians or Afro-Brazilians).14
PATIENTS AND METHODS
This study was approved by the Ethics Committee of
the Faculty of Medicine, University of São Paulo, Brazil.
One-hundred and eight unrelated clinically and labora-
tory diagnosed CF patients were enrolled in this study to
determine the frequency of ∆F508-mutated alleles in this
population. We aimed at comparing our data with those pre-
viously reported with respect to Brazilian CF patients.5-13
Two milliliters of whole blood samples (EDTA, Becton
Dickinson) were drawn from patients after informed con-
sent. DNA extraction was performed according to a previ-
ously described salting out protocol.15 The presence of the
∆F508 mutation was determined by means of a classical
PCR followed by detection of amplification products in sil-
ver-stained polyacrylamide gel electrophoresis according
to a previously described protocol,16,17 which was modified
to fit our laboratory conditions.
DNA samples of non-carrier subjects (having 2 wild-
type alleles) yielded a unique 98 bp (base-pair) fragment,
whereas samples from heterozygous patients had 2 ampli-
fied fragments, 1 of 98 bp and 1 of 95 bp (lacking 3 base-
pairs), and finally DNA from homozygous individuals had
only 1 amplified fragment of 95 bp. Amplifications were
performed as follows: 10 ng of genomic DNA, 0.4 mM of
each of the primers “sense” C16B (5’-
GTTTTCCTGGATTATGCCTGGGCA-3’ and “anti-sense”
C16D (5’- GTTGGCATGCTTTGATGACGTTTC); 1.5 mM
of MgCl2 , 2.5 U of Taq DNA polymerase (Amersham-
Pharmacia Biotech). After an initial denaturation step of 5
min. at 95°C, 40 cycles of amplification were performed in
a Minicycler PT-150, (MJ Research). Cycles consisted of 1
min. at 95°C, 1 min. at 55°C and 1 min. at 72°C, and were
followed by a final extension step of 5 min. at 72°C.
Ten microliters of amplification products were analyzed
by means of vertical electrophoresis in 8% polyacrylamide
gels under non-denaturing conditions for 4 h and 30 min.
(25 mA, 450 V, 20 W) in a refrigerated electrophoresis appa-
ratus (Höefer SE 660, Amersham-Pharmacia Biotech). Then,
gels were silver-stained, washed, and fixed according a pre-
viously described protocol18 and afterwards were dried in a
gel dryer (BioRad, USA), at 80°C for 2 h and 30 min.
RESULTS
Among the 108 patients studied, we found 23 (21.3%)
homozygous for the ∆F508 deletion mutation, 50 hetero-
zygous (46.3%), and 35 (32.4%) non-carriers. In terms of
alleles, there were 96 mutated (96/216 or 44.45%) and 120
wild-type ones (120/216 or 55.5%).
Table 1 summarizes the data of 14 Brazilian studies per-
formed in cystic fibrosis patients according to the number of
alleles studied, the region of the country, and the frequency
of ∆F508-mutated alleles. Briefly, the data show that the to-
tality of reports included south or southeast regions patients,
with a great variability of either ∆F508 mutation frequency
as well as other CF-associated mutations (21.0 to 81.0%).
Table 1 - Brazilian studies performed in cystic fibrosis
patients according to the number of alleles studied, the
region of the country, and the frequency of ∆F508-mutated
alleles.
No. Region of Frequency Reference
chromosomes Brazil / State (%)
48 Southeast 33.0 6
(São Paulo)
34 Southeast 35.0 7
(Rio de Janeiro)
120 South 49.0 8
(Rio Grande do Sul)
48 South 27.0 8
(Santa Catarina)
34 South 44.0 8
(Paraná)
116 Southeast 52.0 8
(São Paulo)
62 Southeast 53.0 8
(Minas Gerais)
120 Southeast 31.7 9
(São Paulo)
122 South 50.8 10
(Rio Grande do Sul)
88 Southeast 30.7 1 1
(Rio de Janeiro)
320 Southeast 48.4 12
State ?
154 South 48.7 1 3
(Rio Grande do Sul)
310 South/ Southeast 81.0 * 14
(Euro-Brazilians)
76 South/ Southeast 21.0 * 14
(Afro-Brazilians)
*The percentage refers to the overall frequency of the 70 most
common CF mutations (not only ∆F508 mutations).
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Figure 1 shows the detection of PCR products in 8%
polyacrylamide gels. Homozygous patients (ho) have two
95 bp products, indicating 2 alleles with the ∆F508 muta-
tion; heterozygous ones (he) have one 95 bp product one
98 bp product, indicating one ∆F508-mutated allele and
one non-carrier (wild type) allele; and finally non-affected
individuals or non-carriers (nc) have two 98 bp products,
indicating 2 non-mutated alleles. The molecular weight
marker used is the 25 bp marker from Invitrogen (USA).
DISCUSSION
The frequency of ∆F508-mutated alleles in the present
study was 44.5%. This frequency is higher than the 33.0%
and the 35.0% described by Martins et al. (1993)6 and De
Miranda et al. (1993)7, respectively, but it is noteworthy that
they studied a limited number of patients (24 in São Paulo
and 17 in Rio de Janeiro). However, Parizotto et al. (1997)9
studied 120 chromosomes from 60 CF patients of the State
of São Paulo and reported that only 31.7% of them had
∆F508-mutated alleles. Similarly, Cabello et al. (1999) de-
scribed a frequency of 30.68% of alleles with the ∆F508 mu-
tation in 88 patients from the State of Rio de Janeiro.11 On
the contrary, Raskin et al. (1993)8 studied 190 patients from
the south and the southeast of Brazil: 60 from Rio Grande
do Sul, 24 from Santa Catarina, 17 from Paraná, 58 from São
Paulo and 31 from Minas Gerais. They found an overall fre-
quency of 47.0% of alleles with the ∆F508 mutation. How-
ever, when the frequencies were considered according to the
state of origin of patients, they found 49.0% in Rio Grande
do Sul, 27.0% in Santa Catarina, 44.0% in Paraná, 52.0% in
São Paulo and 53.0% in Minas Gerais. In addition,
Bernardino et al. (2000)12 and Streit et al. (2003)13 found
higher frequencies of alleles with the ∆F508 mutation that
were very similar (48.4% and 48.7%, respectively), but the
former study did not mention whether the patients were all
from the State of São Paulo, and the latter was carried out in
the State of Rio Grande do Sul, in the south region of Brazil.
Raskin et al. in a series of articles that analyzed the frequency
of the ∆F508 mutation as well as other common mutations
associated with CF in Brazilian patients19,20,14 initially cited
a frequency of 47.0% in Brazilian patients of European ori-
gin,19 then a frequency ranging from 30.7 to 50.8%,20 and
finally a striking difference in a screening for the 70 most
common CF mutations (including ∆F508) between Euro-Bra-
zilians (75.0%) and Afro-Brazilians (21.0%).14
It is interesting to point out that in all polyacrylamide
gels that were performed on heterozygous samples, 2 frag-
ments of molecular weights between 100 bp and 125 bp
were present. This phenomenon has already been observed
and reported,21 but the relevance of these DNA fragments
has still to be investigated. Nevertheless, these spurious
fragments act as DNA markers for alleles that are hetero-
zygous for the ∆F508 mutation.
The present study added 216 chromosomes to the list
of 1,652 already investigated in Brazilian CF patients with
respect to the ∆F508 mutation, of which only 284 alleles
are certain to belong to patients of the State of São Paulo.
The 44.45% of ∆F508-mutated alleles cited in the present
study is within the range of frequencies already reported.
Furthermore, all performed Brazilian studies (including
ours) tend to indicate a lower frequency of ∆F508-mutated
alleles in Brazil in comparison to European and North
American studies (around 70.0%). This is probably due to
the higher genetic heterogeneity of our population. These
results emphasize the need to re-evaluate the cost vs. ben-
efit ration regarding DNA-based tests for genetic screening
in highly heterogeneous populations such as the Brazilian
because they will be surely less effective in detecting ∆F508
mutations as well as in other common CF mutations.
Figure 1 - Detection of ∆F508 mutation by PCR in 8% polyacrylamide
gels. Lanes 1, 3, 6, 7, 8, 9 and 15 are heterozygous patients (one 98 bp
fragment and one 95 bp one). Lanes 2, 5 and 11 are homozygous
patients (two 95 bp fragments), and lanes 4, 12, 13 and 14 are non-
carrier patients (two 98 bp fragments). Lane 16 presents the
heterozygous control, lane 17 the homozygous control and lane 18
the non-carrier control. Molecular weight (MW) is the 25 bp molecular
weight marker (Invitrogen, USA). The 5 MW fragments are (from top
to bottom): 150 bp, 125 bp, 100 bp, 75 bp and 50 bp.
RESUMO
OKAY TS e col. Freqüência da mutação ∆F508 em 108 paci-
entes com fibrose cística de São Paulo: comparação com da-
dos de estudos brasileiros. CLINICS 60(2):131-134, 2005.
OBJETIVO: Analisar a freqüência da mutação delta
F508 (∆F508) em 108 pacientes não aparentados, com
fibrose cística e comparou os resultados com os dados de
134
CLINICS 60(2):131-134, 2005Frequency of the ∆F508 mutation in 108 cystic fibrosis patients in são paulo
Okay TS et al.
outros estudos brasileiros. A fibrose cística (CF) constitui a
doença genética mais comum em populações caucasianas,
sendo a ∆F508 a mais freqüente dentre as mutações relaci-
onadas à doença.
MÉTODO: A freqüência da ∆F508 foi analisada por
meio da Reação em Cadeia da Polimerase (PCR) seguida
de detecção em géis de poliacrilamida a 8%.
RESULTADOS: Vinte e três dos 108 pacientes foram
homozigotos para a mutação (21,3%), 50 foram
heterozigotos (46,3%) e os 35 restantes não eram portado-
res da ∆F508 (32,4%). Em termos de alelos, foram observa-
dos 96 mutados (44,45%) e 120 do tipo selvagem (55,55%),
ou seja, não portadores da mutação.
CONCLUSÃO: A freqüência de 44,45% de alelos
mutados encontrada no estudo é mais elevada que os 33,0%
descritos em pesquisa realizada em São Paulo em 1993, e
ligeiramente mais baixa que os 48,0% encontrados em re-
latos mais recentes. Além disso, nossos resultados corrobo-
raram a idéia de que a freqüência da mutação ∆F508 é mais
baixa no Brasil em comparação a países europeus e nos Es-
tados Unidos da América (cerca de 70,0%), provavelmente
devido a maior miscigenação racial. Estas observações te-
rão que ser consideradas antes da implementação de testes
genéticos de triagem no Brasil.
UNITERMOS: CFTR. ∆F508. Mutação. Deleção.
Fibrose cística.
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